GemVax & KAEL "GV1001, Proven Potential for Depression Treatment"

[Financial News] GemVax & KAEL recently announced on the 14th that a paper proving the antidepressant effects of GV1001 has been published in the international journal 'Behavioural Brain Research'. This study, conducted by Professor Yu Seong-un's team from the Daegu Gyeongbuk Institute of Science and Technology (DGIST) Department of Brain Science, confirmed the effects of GV1001 in alleviating depression-like behavior and memory decline induced by stress. The title of the paper is 'Antidepressant Effects of Human Telomerase-Derived Peptide GV1001 in a Chronic Restraint Stress Animal Model'.
The antidepressant effects of GV1001 were found to be closely related to the recovery of the function of the 'hypothalamic-pituitary-adrenal axis (HPA axis)', which regulates the stress response. The HPA axis is a central endocrine system that regulates the stress response. When this axis is excessively activated, depressive symptoms such as mood decline, sleep disorders, appetite changes, and cognitive function decline are induced.
According to the paper, the number of c-Fos expressing cells in the hypothalamus significantly increased under stress conditions, but significantly decreased in the animal model administered with GV1001.
c-Fos is a representative immediate early gene that appears rapidly when nerve cells are stimulated, serving as a molecular marker of the brain's sensitivity to stress responses.
The study results showed that GV1001 contributed to the balance recovery of HPA axis function and normalized blood stress hormone (corticosterone) levels, improving various symptoms caused by depression.
The researchers explained, "This study suggests the potential of GV1001 to effectively control the pathophysiology of stress-based depression by inhibiting the hyperactivity of nerve cells in the hypothalamus and stabilizing HPA axis function."
A GemVax representative stated, "This paper is significant as it is the first study to scientifically present the antidepressant efficacy of GV1001, which shows various neuroprotective effects, and confirm that GV1001 regulates the hyperactivation of the major neuroendocrine system, the HPA axis. We will continue to scientifically prove the various efficacies of GV1001 through ongoing research."

vrdw88@fnnews.com Kang Jung-mo Reporter